ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
O-GlcNAcylation Regulation of SNAP29-Dependent Autophagy Activation Dictates Chemoresistance in Gastric Cancer.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Chemoresistance remains a major obstacle in gastric cancer (GC) treatment, particularly to standard fluoropyrimidine and platinum regimens. O-GlcNAc transferase (OGT) and O-linked β-N-acetylglucosamine modification (O-GlcNAcylation) are frequently elevated in cancers, yet their specific role in GC chemotherapy remains poorly defined. Contrary to its typical oncogenic function, this study demonstrates that low OGT/O-GlcNAcylation is associated with resistance to 5-fluorouracil (5-FU) or oxaliplatin (OXA) in GC. Clinically, high OGT expression correlates with better prognosis in patients receiving fluoropyrimidine/platinum chemotherapy. Functionally, OGT knockdown or O-GlcNAcylation inhibition promotes chemoresistance both in vitro and in vivo. Mechanistically, OGT interacts with and O-GlcNAcylates synaptosomal-associated protein 29 (SNAP29) at Ser
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.